In CRC, CAF-derived CCL2 upregulates FGFR4, which plays a role in tumor-matrix interactions and promotes EMT, which may constitute an essential factor in CRC resistance to 5-FU and oxaliplatin [294]. The gene discussed is CCL2; the disease is neoplasm.